Zobrazeno 1 - 10
of 10
pro vyhledávání: '"R. M. Crooke"'
Autor:
Philip L. Felgner, Carl J. Wheeler, Jiin Felgner, Y. J. Tsai, D Mirejovsky, R M Crooke, C F Bennett, C.N. Sridhar
Publikováno v:
Journal of Drug Targeting. 5:149-162
A series of 2,3-dialkyloxypropyl quaternary ammonium lipids containing hydroxyalkyl chains on the quaternary amine were synthesized, formulated with dioleoylphosphatidylethanolamine (DOPE) and assayed for their ability to enhance the activity of an i
Publikováno v:
Biochemical pharmacology. 62(3)
The pharmacokinetics of ISIS 1082, a 21-base heterosequence phosphorothioate oligodeoxynucleotide, were characterized within rodent whole liver, and cellular and subcellular compartments. Cross-species comparisons were performed using Sprague-Dawley
Autor:
M, Butler, R M, Crooke, M J, Graham, K M, Lemonidis, M, Lougheed, S F, Murray, D, Witchell, U, Steinbrecher, C F, Bennett
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 292(2)
It has been suggested that binding of phosphorothioate oligodeoxynucleotides (P=S ODNs) to macrophage scavenger receptors (SR-AI/II) is the primary mechanism of P=S ODN uptake into cells in vivo. To address the role of scavenger receptors in P=S ODN
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 292(1)
Phosphorothioate antisense oligodeoxynucleotides are novel therapeutic agents designed to selectively and specifically inhibit production of various disease-related gene products. In vivo pharmacokinetic experiments indicate that these molecules are
Autor:
M J, Graham, S T, Crooke, D K, Monteith, S R, Cooper, K M, Lemonidis, K K, Stecker, M J, Martin, R M, Crooke
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 286(1)
In the rat, the liver represents a major site of phosphorothioate oligodeoxynucleotide deposition after i.v. administration. For this reason, we examined the intracellular fate of ISIS 1082, a 21-base heterosequence phosphorothioate oligodeoxynucleot
Autor:
R. M. Crooke
Publikováno v:
Antisense Research and Application ISBN: 9783642637308
Eighteen years ago, Zamecnik and Stephenson used synthetic antisense oligonucleotides to inhibit Rous sarcoma virus replication and RNA translation in a cellular system ([Zamecnix and Stephenson 1978]). Since that time, enormous progress has been mad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d41fad22c4f4c2e0ef3af3ade5a04145
https://doi.org/10.1007/978-3-642-58785-6_3
https://doi.org/10.1007/978-3-642-58785-6_3
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 275(1)
ISIS 2105 (Afovirsen), a 20-mer phosphorothioate oligonucleotide that inhibits the production of a gene product essential to the growth of human papillomavirus, is in phase II clinical trials for the treatment of genital warts induced by human papill
Phosphorothioate oligonucleotides complementary to mRNA of the human cytomegalovirus (HCMV) DNA polymerase gene or to RNA transcripts of the major immediate-early regions 1 and 2 (IE1 and IE2) of HCMV were evaluated for antiviral activity in a 96-wel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50b855b181a4481cc874bf5dc30d0b0
https://europepmc.org/articles/PMC188097/
https://europepmc.org/articles/PMC188097/
Publikováno v:
Antimicrobial agents and chemotherapy. 36(3)
ISIS 1082, a phosphorothioate oligonucleotide targeted to a translation initiation codon of herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) virion capsid protein UL13 inhibits in vitro viral replication. To better understa
Autor:
R M, Crooke
Publikováno v:
Anti-cancer drug design. 6(6)
The ability to rationally design antisense drugs and the theoretical selectivity of these compounds for specific genomic and viral mRNA targets make their use as therapeutic agents extremely attractive. Pharmacologic data emerging from our and other